These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
326 related articles for article (PubMed ID: 16144512)
21. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. Burnier M; Zanchi A J Hypertens; 2006 Jan; 24(1):11-25. PubMed ID: 16331093 [TBL] [Abstract][Full Text] [Related]
22. Renoprotect and blood pressure lowering effect of low-dose hydrochlorothiazide added to intensive renin-angiotensin inhibition in hypertensive patients with chronic kidney disease. Abe M; Okada K; Maruyama T; Matsumoto K Int J Clin Pharmacol Ther; 2009 Aug; 47(8):525-32. PubMed ID: 19640361 [TBL] [Abstract][Full Text] [Related]
23. [Renin-angiotensin system in diabetic nephropathy]. Luño J Nefrologia; 2005; 25 Suppl 2():73-81. PubMed ID: 16050407 [TBL] [Abstract][Full Text] [Related]
24. Renin angiotensin system blockade and nephropathy: why is it being called into question, and should it be? Hollenberg NK; Epstein M Clin J Am Soc Nephrol; 2006 Sep; 1(5):1046-8. PubMed ID: 17699325 [No Abstract] [Full Text] [Related]
25. Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients. Renke M; Tylicki L; Rutkowski P; Wojnarowski K; Lysiak-Szydlowska W; Rutkowski B Scand J Urol Nephrol; 2005; 39(6):511-7. PubMed ID: 16303729 [TBL] [Abstract][Full Text] [Related]
26. Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin. Lebel M; Rodrigue ME; Agharazii M; Larivière R Am J Hypertens; 2006 Dec; 19(12):1286-92. PubMed ID: 17161776 [TBL] [Abstract][Full Text] [Related]
27. [The renin-angiotensin-aldosterone system -- more complex as previously thought]. Wolf G Med Klin (Munich); 2005 Aug; 100(8):471-7. PubMed ID: 16096728 [TBL] [Abstract][Full Text] [Related]
28. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy. Krairittichai U; Chaisuvannarat V J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520 [TBL] [Abstract][Full Text] [Related]
29. Renoprotective effect of the addition of losartan to ongoing treatment with an angiotensin converting enzyme inhibitor in type-2 diabetic patients with nephropathy. Abe H; Minatoguchi S; Ohashi H; Murata I; Minagawa T; Okuma T; Yokoyama H; Takatsu H; Takaya T; Nagano T; Osumi Y; Kakami M; Tsukamoto T; Tanaka T; Hiei K; Fujiwara H Hypertens Res; 2007 Oct; 30(10):929-35. PubMed ID: 18049024 [TBL] [Abstract][Full Text] [Related]
30. Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy. Van Buren PN; Adams-Huet B; Nguyen M; Molina C; Toto RD Clin J Am Soc Nephrol; 2014 Feb; 9(2):295-301. PubMed ID: 24408116 [TBL] [Abstract][Full Text] [Related]
32. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Andersen S; Tarnow L; Rossing P; Hansen BV; Parving HH Kidney Int; 2000 Feb; 57(2):601-6. PubMed ID: 10652037 [TBL] [Abstract][Full Text] [Related]
33. Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study. Kurokawa K; Chan JC; Cooper ME; Keane WF; Shahinfar S; Zhang Z Clin Exp Nephrol; 2006 Sep; 10(3):193-200. PubMed ID: 17009077 [TBL] [Abstract][Full Text] [Related]
35. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy. Pathak JV; Dass EE Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372 [TBL] [Abstract][Full Text] [Related]
36. Combined therapy of cilazapril and losartan has no additive effects in ameliorating adriamycin-induced glomerulopathy. Kim HJ; Ryu JH; Han SW; Park IK; Paik SS; Park MH; Paik DJ; Chung HS; Kim SW; Lee JU Nephron Physiol; 2004; 97(4):p58-65. PubMed ID: 15331931 [TBL] [Abstract][Full Text] [Related]
37. The preclinical basis of the therapeutic evaluation of losartan. Timmermans PB; Wong PC; Chiu AT; Smith RD J Hypertens Suppl; 1995 Jul; 13(1):S1-13. PubMed ID: 18800450 [TBL] [Abstract][Full Text] [Related]
39. Have the renin-angiotensin-aldosterone system perturbations in cardiovascular disease been exhausted? Mansur SJ; Hage FG; Oparil S Curr Cardiol Rep; 2010 Nov; 12(6):450-63. PubMed ID: 20827517 [TBL] [Abstract][Full Text] [Related]
40. Angiotensin receptor blockers: RAAS blockade and renoprotection. Ruilope LM Curr Med Res Opin; 2008 May; 24(5):1285-93. PubMed ID: 18366863 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]